Prostate Cancer - Results from #120

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer. October 15, 2024

Systemic immune-inflammation index is associated with high risk for prostate cancer among the U.S. elderly: Evidence from NHANES 2001-2010. October 15, 2024

The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617. October 15, 2024

PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients October 14, 2024

Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial October 14, 2024

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. October 14, 2024

Testing home-based exercise strategies in underserved minority cancer patients undergoing chemotherapy (THRIVE) trial: a study protocol. October 14, 2024

Nivolumab in patients with metastatic castration-resistant prostate cancer with and without DNA repair defects. October 14, 2024

Radiotherapy and theranostics: a Lancet Oncology Commission. October 14, 2024

Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer. October 14, 2024

Post-Treatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30). October 14, 2024

Loss of PI5P4Kα slows the progression of a Pten mutant basal cell model of prostate cancer. October 14, 2024

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). October 14, 2024

Detection of Germline Variants in Patients with Localized and Metastatic Prostate Cancer through Guideline-Based Testing. October 14, 2024

Methylation-based immune deconvolution in prostate cancer patients before and after radical prostatectomy. October 14, 2024

The Immune Microenvironment in Prostate Cancer: A Comprehensive Review. October 14, 2024

Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx October 11, 2024

Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics. October 11, 2024

Peripheral blood interferon responses to toll-like receptor 1/2 signaling associate with longer survival in men with metastatic prostate cancer treated with Sipleucel-T. October 11, 2024

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression. October 11, 2024

Page 7 of 1436